NCT00251498View on ClinicalTrials.gov

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 2007

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Cetuximab

Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15

Trial Locations (1)

77042

Veeda Oncology, Houston